Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO
Pavelka, Karel, Bruyère, Olivier, Cooper, Cyrus, Kanis, John A., Leeb, Burkhard F., Maheu, Emmanuel, Martel-Pelletier, Johanne, Monfort, Jordi, Pelletier, Jean-Pierre, Rizzoli, Rene and Reginster, Jean-Yves. (2016). Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs and Aging. 33(2), pp. 75 - 85. https://doi.org/10.1007/s40266-016-0347-4
|Authors||Pavelka, Karel, Bruyère, Olivier, Cooper, Cyrus, Kanis, John A., Leeb, Burkhard F., Maheu, Emmanuel, Martel-Pelletier, Johanne, Monfort, Jordi, Pelletier, Jean-Pierre, Rizzoli, Rene and Reginster, Jean-Yves|
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.
|Journal||Drugs and Aging|
|Journal citation||33 (2), pp. 75 - 85|
|Publisher||Springer International Publishing|
|Digital Object Identifier (DOI)||https://doi.org/10.1007/s40266-016-0347-4|
|Open access||Open access|
|Page range||75 - 85|
|Research Group||Institute for Health and Ageing|
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
|Place of publication||Switzerland|
0views this month
0downloads this month